BioCardia, Inc. (BCDA) 10-Year Financial Performance & Capital Metrics

BCDA • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

AboutBioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.Show more

Revenue $58K -87.8%
EBITDA -$8M +31.4%
Net Income -$8M +31.3%
EPS (Diluted) -2.90 +64.6%
Gross Margin -7463.79% -391.1%
EBITDA Margin -13679.31% -464.4%
Operating Margin -13794.83% -465.1%
Net Margin -13700% -464.8%
ROE -949.34% -34.9%
ROIC -
Debt/Equity 1.14
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 15 (bottom 15%)
✗Sales declining 39.4% over 5 years
✗Shares diluted 94.3% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-18.1%

5Y-39.41%

3Y-61.48%

TTM-100%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-10.59%

EPS CAGR

10Y-

5Y-

3Y-

TTM-5542.65%

ROCE

10Y Avg-349.43%

5Y Avg-562.14%

3Y Avg-864.6%

Latest-2046.29%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	517K	576K	479K	625K	710K	145K	1.01M	1.35M	477K	58K
Revenue Growth %	0.21%	0.11%	-0.17%	0.3%	0.14%	-0.8%	6%	0.33%	-0.65%	-0.88%
Cost of Goods Sold+	1.06M	746K	690K	517K	358K	4K	640K	8.83M	7.73M	4.39M
COGS % of Revenue	2.05%	1.3%	1.44%	0.83%	0.5%	0.03%	0.63%	6.53%	16.2%	75.64%
Gross Profit+	-1.68M	-170K	-211K	108K	352K	141K	375K	-7.48M	-7.25M	-4.33M
Gross Margin %	-3.24%	-0.3%	-0.44%	0.17%	0.5%	0.97%	0.37%	-5.53%	-15.2%	-74.64%
Gross Profit Growth %	0.11%	0.9%	-0.24%	1.51%	2.26%	-0.6%	1.66%	-20.95%	0.03%	0.4%
Operating Expenses+	198K	7.44M	12.19M	14.21M	14.56M	15.67M	13.01M	4.42M	4.39M	3.67M
OpEx % of Revenue	0.38%	12.91%	25.46%	22.74%	20.51%	108.07%	12.81%	3.27%	9.21%	63.31%
Selling, General & Admin	198K	4.11M	6.39M	5.76M	6M	5.86M	5.09M	0	0	0
SG&A % of Revenue	0.38%	7.13%	13.35%	9.21%	8.45%	40.42%	5.01%	-	-	-
Research & Development	1.52M	3.33M	5.8M	8.45M	8.56M	9.81M	8.56M	8.83M	7.73M	4.39M
R&D % of Revenue	2.94%	5.78%	12.11%	13.52%	12.06%	67.65%	8.43%	6.53%	16.2%	75.64%
Other Operating Expenses	-1.52M	-2K	2K	-3K	0	0	-640K	-4.42M	-3.33M	-715K
Operating Income+	319K	-7.61M	-12.4M	-14.1M	-14.21M	-15.53M	-12.63M	-11.9M	-11.64M	-8M
Operating Margin %	0.62%	-13.21%	-25.9%	-22.56%	-20.02%	-107.1%	-12.44%	-8.8%	-24.41%	-137.95%
Operating Income Growth %	0.38%	-24.85%	-0.63%	-0.14%	-0.01%	-0.09%	0.19%	0.06%	0.02%	0.31%
EBITDA+	366K	-7.57M	-12.33M	-14.01M	-13.66M	-14.96M	-12.57M	-11.82M	-11.56M	-7.93M
EBITDA Margin %	0.71%	-13.14%	-25.73%	-22.42%	-19.24%	-103.19%	-12.38%	-8.74%	-24.23%	-136.79%
EBITDA Growth %	0.32%	-21.68%	-0.63%	-0.14%	0.03%	-0.1%	0.16%	0.06%	0.02%	0.31%
D&A (Non-Cash Add-back)	47K	39K	78K	88K	551K	566K	60K	82K	84K	67K
EBIT	319K	-8.57M	-12.31M	-13.99M	-14.6M	-15M	-12.63M	-11.9M	-11.64M	-8M
Net Interest Income+	3K	-1.74M	95K	118K	-25K	18K	9K	-6K	0	0
Interest Income	3K	0	95K	118K	87K	21K	9K	0	0	0
Interest Expense	0	1.74M	0	0	112K	3K	0	6K	0	0
Other Income/Expense	3K	-2.7M	97K	115K	-496K	525K	7K	-6K	73K	55K
Pretax Income+	322K	-10.31M	-12.31M	-13.99M	-14.71M	-15M	-12.62M	-11.91M	-11.57M	-7.95M
Pretax Margin %	0.62%	-17.9%	-25.7%	-22.38%	-20.72%	-103.48%	-12.44%	-8.81%	-24.26%	-137%
Income Tax+	0	0	0	-115K	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	322K	-10.31M	-12.31M	-13.99M	-14.71M	-15M	-12.62M	-11.91M	-11.57M	-7.95M
Net Margin %	0.62%	-17.9%	-25.7%	-22.38%	-20.72%	-103.48%	-12.43%	-8.81%	-24.26%	-137%
Net Income Growth %	0.38%	-33.02%	-0.19%	-0.14%	-0.05%	-0.02%	0.16%	0.06%	0.03%	0.31%
Net Income (Continuing)	322K	-10.31M	-12.31M	-13.99M	-14.71M	-15M	-12.62M	-11.91M	-11.57M	-7.95M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	27.86	-166.33	-43.50	-48.80	-39.15	-22.20	-11.19	-10.05	-8.19	-2.90
EPS Growth %	0.36%	-6.97%	0.74%	-0.12%	0.2%	0.43%	0.5%	0.1%	0.19%	0.65%
EPS (Basic)	27.86	-166.33	-43.50	-48.80	-39.15	-22.20	-11.19	-10.05	-8.19	-2.90
Diluted Shares Outstanding	11.56K	61.99K	282.67K	284.28K	376.29K	674.58K	1.13M	1.18M	1.41M	2.74M
Basic Shares Outstanding	11.56K	61.99K	282.67K	284.28K	376.29K	674.58K	1.13M	1.18M	1.41M	2.74M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	13.88M	21.92M	13.31M	6.22M	6.38M	22.66M	13.48M	7.86M	1.46M	2.62M
Cash & Short-Term Investments	13.84M	21.35M	12.69M	5.36M	5.58M	21.41M	12.87M	7.36M	1.1M	2.37M
Cash Only	13.84M	21.35M	12.69M	5.36M	5.58M	21.41M	12.87M	7.36M	1.1M	2.37M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	74K	95K	274K	147K	232K	147K	201K	63K	0
Days Sales Outstanding	-	46.89	72.39	160.02	75.57	584	52.86	54.26	48.21	-
Inventory	759K	135K	191K	141K	4K	0	0	0	0	0
Days Inventory Outstanding	261.11	66.05	101.04	99.55	4.08	-	-	-	-	-
Other Current Assets	0	0	0	0	0	618K	0	300K	295K	251K
Total Non-Current Assets+	193K	165K	223K	199K	1.3M	766K	2.24M	1.93M	1.53M	1.1M
Property, Plant & Equipment	150K	111K	169K	145K	1.25M	712K	2.06M	1.76M	1.36M	931K
Fixed Asset Turnover	3.45x	5.19x	2.83x	4.31x	0.57x	0.20x	0.49x	0.77x	0.35x	0.06x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	43K	54K	54K	54K	54K	54K	172K	171K	171K	171K
Total Assets+	13.88M	22.08M	13.54M	6.42M	7.68M	23.42M	15.72M	9.79M	2.99M	3.72M
Asset Turnover	0.04x	0.03x	0.04x	0.10x	0.09x	0.01x	0.06x	0.14x	0.16x	0.02x
Asset Growth %	0.02%	0.59%	-0.39%	-0.53%	0.2%	2.05%	-0.33%	-0.38%	-0.69%	0.25%
Total Current Liabilities+	10K	1.44M	2.33M	2.55M	4M	4.25M	3.71M	3.58M	3.61M	2.32M
Accounts Payable	542K	525K	902K	1.02M	914K	746K	507K	683K	890K	385K
Days Payables Outstanding	186.46	256.87	477.14	720.12	931.87	68.07K	289.15	28.22	42.05	32.03
Short-Term Debt	5.67M	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	39K	137K	891K	757K	0	0	1000K	965K	561K	532K
Other Current Liabilities	2.09M	0	724K	480K	732K	1.39M	0	0	0	378K
Current Ratio	1387.60x	15.18x	5.71x	2.44x	1.59x	5.33x	3.63x	2.19x	0.40x	1.13x
Quick Ratio	1311.70x	15.08x	5.63x	2.39x	1.59x	5.33x	3.63x	2.19x	0.40x	1.13x
Cash Conversion Cycle	-	-143.93	-303.72	-460.55	-852.22	-	-	-	-	-
Total Non-Current Liabilities+	0	56K	81K	77K	1.3M	0	1.63M	1.32M	982K	566K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	614K	0	1.63M	1.32M	982K	566K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	56K	81K	77K	691K	0	0	0	0	0
Total Liabilities	10K	1.5M	2.41M	2.63M	5.31M	4.25M	5.34M	4.9M	4.59M	2.89M
Total Debt+	5.67M	0	0	0	1.14M	614K	1.87M	1.63M	1.31M	951K
Net Debt	-8.17M	-21.35M	-12.69M	-5.36M	-4.44M	-20.79M	-11M	-5.73M	212K	-1.42M
Debt / Equity	0.41x	-	-	-	0.48x	0.03x	0.18x	0.33x	-	1.14x
Debt / EBITDA	15.50x	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-22.32x	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-4.38x	-	-	-126.90x	-5176.33x	-	-1983.50x	-	-
Total Equity+	13.87M	20.58M	11.13M	3.79M	2.37M	19.18M	10.38M	4.89M	-1.6M	837K
Equity Growth %	0.02%	0.48%	-0.46%	-0.66%	-0.38%	7.09%	-0.46%	-0.53%	-1.33%	1.52%
Book Value per Share	1199.69	332.04	39.36	13.34	6.30	28.43	9.20	4.14	-1.14	0.31
Total Shareholders' Equity	13.87M	20.58M	11.13M	3.79M	2.37M	19.18M	10.38M	4.89M	-1.6M	837K
Common Stock	230K	458K	38K	43K	7K	16K	17K	20K	2K	5K
Retained Earnings	-12.13M	-60.14M	-72.45M	-86.36M	-101.07M	-116.07M	-128.7M	-140.6M	-152.18M	-160.12M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-46.03M	-771K	-758K	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	331K	-5.52M	-8.67M	-11.07M	-9.45M	-12.36M	-10.37M	-10.56M	-9.97M	-8.03M
Operating CF Margin %	0.64%	-9.59%	-18.1%	-17.71%	-13.3%	-85.22%	-10.21%	-7.81%	-20.91%	-138.38%
Operating CF Growth %	0.55%	-17.68%	-0.57%	-0.28%	0.15%	-0.31%	0.16%	-0.02%	0.06%	0.2%
Net Income	322K	-10.31M	-12.31M	-13.99M	-14.71M	-15M	-12.62M	-11.91M	-11.57M	-7.95M
Depreciation & Amortization	47K	39K	78K	88K	111K	68K	60K	82K	84K	67K
Stock-Based Compensation	283K	942K	2.71M	2.77M	2.72M	2.95M	1.66M	1.18M	1.03M	741K
Deferred Taxes	0	1.56M	0	0	910K	0	0	0	0	0
Other Non-Cash Items	-181K	1.74M	2.56M	2.96M	112K	-506K	599K	295K	354K	329K
Working Capital Changes	9K	510K	852K	56K	1.41M	133K	-63K	-214K	129K	-1.22M
Change in Receivables	65K	33K	-21K	-179K	127K	-703K	703K	-54K	115K	97K
Change in Inventory	-82K	27K	-56K	49K	136K	4K	0	0	0	0
Change in Payables	9K	-17K	377K	119K	171K	-168K	-239K	4K	184K	-316K
Cash from Investing+	-125K	18.92M	-136K	-66K	-146K	-32K	-116K	-70K	-12K	-6K
Capital Expenditures	-125K	0	-136K	-66K	-146K	-32K	-116K	-70K	-12K	-6K
CapEx % of Revenue	0.24%	-	0.28%	0.11%	0.21%	0.22%	0.11%	0.05%	0.03%	0.1%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	-96K	18.92M	-66K	0	0	0	0	0	0
Cash from Financing+	7.57M	4.4M	144K	3.8M	9.82M	28.21M	1.95M	5.12M	3.73M	9.3M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	22K	144K	0	-1.26M	-2.79M	-54K	-418K	-662K	-1.25M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	206K	-5.52M	-8.81M	-11.13M	-9.59M	-12.39M	-10.48M	-10.63M	-9.99M	-8.03M
FCF Margin %	0.4%	-9.59%	-18.39%	-17.82%	-13.51%	-85.44%	-10.33%	-7.86%	-20.94%	-138.48%
FCF Growth %	0.28%	-27.81%	-0.59%	-0.26%	0.14%	-0.29%	0.15%	-0.01%	0.06%	0.2%
FCF per Share	17.82	-89.08	-31.16	-39.17	-25.49	-18.37	-9.29	-9.00	-7.07	-2.93
FCF Conversion (FCF/Net Income)	1.03x	0.54x	0.70x	0.79x	0.64x	0.82x	0.82x	0.89x	0.86x	1.01x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	2.35%	-59.86%	-77.64%	-187.53%	-477.41%	-139.27%	-85.42%	-155.98%	-703.62%	-949.34%
Return on Invested Capital (ROIC)	3.62%	-231.57%	-	-	-	-	-	-	-	-
Gross Margin	-323.98%	-29.51%	-44.05%	17.28%	49.58%	97.24%	36.95%	-553.4%	-1519.71%	-7463.79%
Net Margin	62.28%	-1789.93%	-2569.52%	-2237.92%	-2071.69%	-10347.59%	-1243.45%	-880.7%	-2425.79%	-13700%
Debt / Equity	0.41x	-	-	-	0.48x	0.03x	0.18x	0.33x	-	1.14x
Interest Coverage	-	-4.38x	-	-	-126.90x	-5176.33x	-	-1983.50x	-	-
FCF Conversion	1.03x	0.54x	0.70x	0.79x	0.64x	0.82x	0.82x	0.89x	0.86x	1.01x
Revenue Growth	21.08%	11.41%	-16.84%	30.48%	13.6%	-79.58%	600%	33.2%	-64.72%	-87.84%

Revenue by Segment

	2019	2020	2022	2023
Collaboration Agreement	-	-	1.35M	477K
Collaboration Agreement Growth	-	-	-	-64.64%
Product	-	-	3K	-
Product Growth	-	-	-	-
License	500K	500K	-	-
License Growth	-	0.00%	-	-
Service	191K	183K	-	-
Service Growth	-	-4.19%	-	-

Frequently Asked Questions

Growth & Financials

BioCardia, Inc. (BCDA) reported $0.1M in revenue for fiscal year 2024. This represents a 383% increase from $0.0M in 2011.

BioCardia, Inc. (BCDA) saw revenue decline by 87.8% over the past year.

BioCardia, Inc. (BCDA) reported a net loss of $8.5M for fiscal year 2024.

Dividend & Returns

BioCardia, Inc. (BCDA) has a return on equity (ROE) of -949.3%. Negative ROE indicates the company is unprofitable.

BioCardia, Inc. (BCDA) had negative free cash flow of $7.5M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

BioCardia, Inc. (BCDA) 10-Year Financial Performance & Capital Metrics

BCDA • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

Revenue $58K -87.8%
EBITDA -$8M +31.4%
Net Income -$8M +31.3%
EPS (Diluted) -2.90 +64.6%
Gross Margin -7463.79% -391.1%
EBITDA Margin -13679.31% -464.4%
Operating Margin -13794.83% -465.1%
Net Margin -13700% -464.8%
ROE -949.34% -34.9%
ROIC -
Debt/Equity 1.14
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 15 (bottom 15%)
✗Sales declining 39.4% over 5 years
✗Shares diluted 94.3% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-18.1%

5Y-39.41%

3Y-61.48%

TTM-100%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-10.59%

EPS CAGR

10Y-

5Y-

3Y-

TTM-5542.65%

ROCE

10Y Avg-349.43%

5Y Avg-562.14%

3Y Avg-864.6%

Latest-2046.29%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	517K	576K	479K	625K	710K	145K	1.01M	1.35M	477K	58K
Revenue Growth %	0.21%	0.11%	-0.17%	0.3%	0.14%	-0.8%	6%	0.33%	-0.65%	-0.88%
Cost of Goods Sold+	1.06M	746K	690K	517K	358K	4K	640K	8.83M	7.73M	4.39M
COGS % of Revenue	2.05%	1.3%	1.44%	0.83%	0.5%	0.03%	0.63%	6.53%	16.2%	75.64%
Gross Profit+	-1.68M	-170K	-211K	108K	352K	141K	375K	-7.48M	-7.25M	-4.33M
Gross Margin %	-3.24%	-0.3%	-0.44%	0.17%	0.5%	0.97%	0.37%	-5.53%	-15.2%	-74.64%
Gross Profit Growth %	0.11%	0.9%	-0.24%	1.51%	2.26%	-0.6%	1.66%	-20.95%	0.03%	0.4%
Operating Expenses+	198K	7.44M	12.19M	14.21M	14.56M	15.67M	13.01M	4.42M	4.39M	3.67M
OpEx % of Revenue	0.38%	12.91%	25.46%	22.74%	20.51%	108.07%	12.81%	3.27%	9.21%	63.31%
Selling, General & Admin	198K	4.11M	6.39M	5.76M	6M	5.86M	5.09M	0	0	0
SG&A % of Revenue	0.38%	7.13%	13.35%	9.21%	8.45%	40.42%	5.01%	-	-	-
Research & Development	1.52M	3.33M	5.8M	8.45M	8.56M	9.81M	8.56M	8.83M	7.73M	4.39M
R&D % of Revenue	2.94%	5.78%	12.11%	13.52%	12.06%	67.65%	8.43%	6.53%	16.2%	75.64%
Other Operating Expenses	-1.52M	-2K	2K	-3K	0	0	-640K	-4.42M	-3.33M	-715K
Operating Income+	319K	-7.61M	-12.4M	-14.1M	-14.21M	-15.53M	-12.63M	-11.9M	-11.64M	-8M
Operating Margin %	0.62%	-13.21%	-25.9%	-22.56%	-20.02%	-107.1%	-12.44%	-8.8%	-24.41%	-137.95%
Operating Income Growth %	0.38%	-24.85%	-0.63%	-0.14%	-0.01%	-0.09%	0.19%	0.06%	0.02%	0.31%
EBITDA+	366K	-7.57M	-12.33M	-14.01M	-13.66M	-14.96M	-12.57M	-11.82M	-11.56M	-7.93M
EBITDA Margin %	0.71%	-13.14%	-25.73%	-22.42%	-19.24%	-103.19%	-12.38%	-8.74%	-24.23%	-136.79%
EBITDA Growth %	0.32%	-21.68%	-0.63%	-0.14%	0.03%	-0.1%	0.16%	0.06%	0.02%	0.31%
D&A (Non-Cash Add-back)	47K	39K	78K	88K	551K	566K	60K	82K	84K	67K
EBIT	319K	-8.57M	-12.31M	-13.99M	-14.6M	-15M	-12.63M	-11.9M	-11.64M	-8M
Net Interest Income+	3K	-1.74M	95K	118K	-25K	18K	9K	-6K	0	0
Interest Income	3K	0	95K	118K	87K	21K	9K	0	0	0
Interest Expense	0	1.74M	0	0	112K	3K	0	6K	0	0
Other Income/Expense	3K	-2.7M	97K	115K	-496K	525K	7K	-6K	73K	55K
Pretax Income+	322K	-10.31M	-12.31M	-13.99M	-14.71M	-15M	-12.62M	-11.91M	-11.57M	-7.95M
Pretax Margin %	0.62%	-17.9%	-25.7%	-22.38%	-20.72%	-103.48%	-12.44%	-8.81%	-24.26%	-137%
Income Tax+	0	0	0	-115K	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	322K	-10.31M	-12.31M	-13.99M	-14.71M	-15M	-12.62M	-11.91M	-11.57M	-7.95M
Net Margin %	0.62%	-17.9%	-25.7%	-22.38%	-20.72%	-103.48%	-12.43%	-8.81%	-24.26%	-137%
Net Income Growth %	0.38%	-33.02%	-0.19%	-0.14%	-0.05%	-0.02%	0.16%	0.06%	0.03%	0.31%
Net Income (Continuing)	322K	-10.31M	-12.31M	-13.99M	-14.71M	-15M	-12.62M	-11.91M	-11.57M	-7.95M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	27.86	-166.33	-43.50	-48.80	-39.15	-22.20	-11.19	-10.05	-8.19	-2.90
EPS Growth %	0.36%	-6.97%	0.74%	-0.12%	0.2%	0.43%	0.5%	0.1%	0.19%	0.65%
EPS (Basic)	27.86	-166.33	-43.50	-48.80	-39.15	-22.20	-11.19	-10.05	-8.19	-2.90
Diluted Shares Outstanding	11.56K	61.99K	282.67K	284.28K	376.29K	674.58K	1.13M	1.18M	1.41M	2.74M
Basic Shares Outstanding	11.56K	61.99K	282.67K	284.28K	376.29K	674.58K	1.13M	1.18M	1.41M	2.74M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	13.88M	21.92M	13.31M	6.22M	6.38M	22.66M	13.48M	7.86M	1.46M	2.62M
Cash & Short-Term Investments	13.84M	21.35M	12.69M	5.36M	5.58M	21.41M	12.87M	7.36M	1.1M	2.37M
Cash Only	13.84M	21.35M	12.69M	5.36M	5.58M	21.41M	12.87M	7.36M	1.1M	2.37M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	74K	95K	274K	147K	232K	147K	201K	63K	0
Days Sales Outstanding	-	46.89	72.39	160.02	75.57	584	52.86	54.26	48.21	-
Inventory	759K	135K	191K	141K	4K	0	0	0	0	0
Days Inventory Outstanding	261.11	66.05	101.04	99.55	4.08	-	-	-	-	-
Other Current Assets	0	0	0	0	0	618K	0	300K	295K	251K
Total Non-Current Assets+	193K	165K	223K	199K	1.3M	766K	2.24M	1.93M	1.53M	1.1M
Property, Plant & Equipment	150K	111K	169K	145K	1.25M	712K	2.06M	1.76M	1.36M	931K
Fixed Asset Turnover	3.45x	5.19x	2.83x	4.31x	0.57x	0.20x	0.49x	0.77x	0.35x	0.06x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	43K	54K	54K	54K	54K	54K	172K	171K	171K	171K
Total Assets+	13.88M	22.08M	13.54M	6.42M	7.68M	23.42M	15.72M	9.79M	2.99M	3.72M
Asset Turnover	0.04x	0.03x	0.04x	0.10x	0.09x	0.01x	0.06x	0.14x	0.16x	0.02x
Asset Growth %	0.02%	0.59%	-0.39%	-0.53%	0.2%	2.05%	-0.33%	-0.38%	-0.69%	0.25%
Total Current Liabilities+	10K	1.44M	2.33M	2.55M	4M	4.25M	3.71M	3.58M	3.61M	2.32M
Accounts Payable	542K	525K	902K	1.02M	914K	746K	507K	683K	890K	385K
Days Payables Outstanding	186.46	256.87	477.14	720.12	931.87	68.07K	289.15	28.22	42.05	32.03
Short-Term Debt	5.67M	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	39K	137K	891K	757K	0	0	1000K	965K	561K	532K
Other Current Liabilities	2.09M	0	724K	480K	732K	1.39M	0	0	0	378K
Current Ratio	1387.60x	15.18x	5.71x	2.44x	1.59x	5.33x	3.63x	2.19x	0.40x	1.13x
Quick Ratio	1311.70x	15.08x	5.63x	2.39x	1.59x	5.33x	3.63x	2.19x	0.40x	1.13x
Cash Conversion Cycle	-	-143.93	-303.72	-460.55	-852.22	-	-	-	-	-
Total Non-Current Liabilities+	0	56K	81K	77K	1.3M	0	1.63M	1.32M	982K	566K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	614K	0	1.63M	1.32M	982K	566K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	56K	81K	77K	691K	0	0	0	0	0
Total Liabilities	10K	1.5M	2.41M	2.63M	5.31M	4.25M	5.34M	4.9M	4.59M	2.89M
Total Debt+	5.67M	0	0	0	1.14M	614K	1.87M	1.63M	1.31M	951K
Net Debt	-8.17M	-21.35M	-12.69M	-5.36M	-4.44M	-20.79M	-11M	-5.73M	212K	-1.42M
Debt / Equity	0.41x	-	-	-	0.48x	0.03x	0.18x	0.33x	-	1.14x
Debt / EBITDA	15.50x	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-22.32x	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-4.38x	-	-	-126.90x	-5176.33x	-	-1983.50x	-	-
Total Equity+	13.87M	20.58M	11.13M	3.79M	2.37M	19.18M	10.38M	4.89M	-1.6M	837K
Equity Growth %	0.02%	0.48%	-0.46%	-0.66%	-0.38%	7.09%	-0.46%	-0.53%	-1.33%	1.52%
Book Value per Share	1199.69	332.04	39.36	13.34	6.30	28.43	9.20	4.14	-1.14	0.31
Total Shareholders' Equity	13.87M	20.58M	11.13M	3.79M	2.37M	19.18M	10.38M	4.89M	-1.6M	837K
Common Stock	230K	458K	38K	43K	7K	16K	17K	20K	2K	5K
Retained Earnings	-12.13M	-60.14M	-72.45M	-86.36M	-101.07M	-116.07M	-128.7M	-140.6M	-152.18M	-160.12M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-46.03M	-771K	-758K	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	331K	-5.52M	-8.67M	-11.07M	-9.45M	-12.36M	-10.37M	-10.56M	-9.97M	-8.03M
Operating CF Margin %	0.64%	-9.59%	-18.1%	-17.71%	-13.3%	-85.22%	-10.21%	-7.81%	-20.91%	-138.38%
Operating CF Growth %	0.55%	-17.68%	-0.57%	-0.28%	0.15%	-0.31%	0.16%	-0.02%	0.06%	0.2%
Net Income	322K	-10.31M	-12.31M	-13.99M	-14.71M	-15M	-12.62M	-11.91M	-11.57M	-7.95M
Depreciation & Amortization	47K	39K	78K	88K	111K	68K	60K	82K	84K	67K
Stock-Based Compensation	283K	942K	2.71M	2.77M	2.72M	2.95M	1.66M	1.18M	1.03M	741K
Deferred Taxes	0	1.56M	0	0	910K	0	0	0	0	0
Other Non-Cash Items	-181K	1.74M	2.56M	2.96M	112K	-506K	599K	295K	354K	329K
Working Capital Changes	9K	510K	852K	56K	1.41M	133K	-63K	-214K	129K	-1.22M
Change in Receivables	65K	33K	-21K	-179K	127K	-703K	703K	-54K	115K	97K
Change in Inventory	-82K	27K	-56K	49K	136K	4K	0	0	0	0
Change in Payables	9K	-17K	377K	119K	171K	-168K	-239K	4K	184K	-316K
Cash from Investing+	-125K	18.92M	-136K	-66K	-146K	-32K	-116K	-70K	-12K	-6K
Capital Expenditures	-125K	0	-136K	-66K	-146K	-32K	-116K	-70K	-12K	-6K
CapEx % of Revenue	0.24%	-	0.28%	0.11%	0.21%	0.22%	0.11%	0.05%	0.03%	0.1%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	-96K	18.92M	-66K	0	0	0	0	0	0
Cash from Financing+	7.57M	4.4M	144K	3.8M	9.82M	28.21M	1.95M	5.12M	3.73M	9.3M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	22K	144K	0	-1.26M	-2.79M	-54K	-418K	-662K	-1.25M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	206K	-5.52M	-8.81M	-11.13M	-9.59M	-12.39M	-10.48M	-10.63M	-9.99M	-8.03M
FCF Margin %	0.4%	-9.59%	-18.39%	-17.82%	-13.51%	-85.44%	-10.33%	-7.86%	-20.94%	-138.48%
FCF Growth %	0.28%	-27.81%	-0.59%	-0.26%	0.14%	-0.29%	0.15%	-0.01%	0.06%	0.2%
FCF per Share	17.82	-89.08	-31.16	-39.17	-25.49	-18.37	-9.29	-9.00	-7.07	-2.93
FCF Conversion (FCF/Net Income)	1.03x	0.54x	0.70x	0.79x	0.64x	0.82x	0.82x	0.89x	0.86x	1.01x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	2.35%	-59.86%	-77.64%	-187.53%	-477.41%	-139.27%	-85.42%	-155.98%	-703.62%	-949.34%
Return on Invested Capital (ROIC)	3.62%	-231.57%	-	-	-	-	-	-	-	-
Gross Margin	-323.98%	-29.51%	-44.05%	17.28%	49.58%	97.24%	36.95%	-553.4%	-1519.71%	-7463.79%
Net Margin	62.28%	-1789.93%	-2569.52%	-2237.92%	-2071.69%	-10347.59%	-1243.45%	-880.7%	-2425.79%	-13700%
Debt / Equity	0.41x	-	-	-	0.48x	0.03x	0.18x	0.33x	-	1.14x
Interest Coverage	-	-4.38x	-	-	-126.90x	-5176.33x	-	-1983.50x	-	-
FCF Conversion	1.03x	0.54x	0.70x	0.79x	0.64x	0.82x	0.82x	0.89x	0.86x	1.01x
Revenue Growth	21.08%	11.41%	-16.84%	30.48%	13.6%	-79.58%	600%	33.2%	-64.72%	-87.84%

Revenue by Segment

	2019	2020	2022	2023
Collaboration Agreement	-	-	1.35M	477K
Collaboration Agreement Growth	-	-	-	-64.64%
Product	-	-	3K	-
Product Growth	-	-	-	-
License	500K	500K	-	-
License Growth	-	0.00%	-	-
Service	191K	183K	-	-
Service Growth	-	-4.19%	-	-

Frequently Asked Questions

Growth & Financials

BioCardia, Inc. (BCDA) reported $0.1M in revenue for fiscal year 2024. This represents a 383% increase from $0.0M in 2011.

BioCardia, Inc. (BCDA) saw revenue decline by 87.8% over the past year.

BioCardia, Inc. (BCDA) reported a net loss of $8.5M for fiscal year 2024.

Dividend & Returns

BioCardia, Inc. (BCDA) has a return on equity (ROE) of -949.3%. Negative ROE indicates the company is unprofitable.

BioCardia, Inc. (BCDA) had negative free cash flow of $7.5M in fiscal year 2024, likely due to heavy capital investments.